Novo Nordisk's Sell-Off Has Gone Too Far

Company Overview - Novo Nordisk A/S (NVO) has a market capitalization of $310 billion, making it one of the largest pharmaceutical companies in Europe [1] - The company operates in two main business segments: Diabetes and Obesity Care, and Rare Disease, with a consolidated turnover of approximately $44 billion on a trailing twelve months (TTM) basis [1]